Claims for Patent: 10,363,308

Summary for Patent: 10,363,308

Title:	Selectively altering microbiota for immune modulation
Abstract:	The invention relates to methods of modulating immune cells in a patient by altering microbiota of the patient. The invention also relates to methods of modulating treatments or therapies in a subject organism by altering microbiota of the subject. The invention also relates to cell populations, systems, arrays, cells, RNA, kits and other means for effecting this. In an example, advantageously selective targeting of a particular species in a human gut microbiota using guided nucleic acid modification is carried out to effect the alteration.
Inventor(s):	Clube; Jasper (London, GB), Sommer; Morten (Copenhagen O, DK), Grondahl; Christian (Copenhagen O, DK)
Assignee:	SNIPR Technologies Limited (London, GB)
Application Number:	16/192,752
Patent Claims:	1. A method for treating a cancer in a patient, wherein the method comprises (a) exposing a microbiota in the patient to a guided nuclease to selectively target the genome of cells of a first species in the microbiota using the guided nuclease, wherein the first species is a bacterial or archaeal species; and simultaneously or sequentially administering to the patient an effective amount of an immunotherapy; and (b) allowing the guided nuclease to cut one or more target nucleotide sequences comprised by first cells of a first strain of the first species, thereby killing the first cells or reducing the growth thereof, whereby the proportion of the first cells comprised by the microbiota is reduced; wherein (c) the selective targeting avoids targeting second cells comprised by the microbiota, wherein the second cells are of a different strain or a different species from the first cells; and (d) the reducing of the proportion of the first cells modulates immune cells in the patient, whereby the efficacy of the immunotherapy is enhanced for treatment of the cancer in the patient. 2. The method of claim 1, wherein the growth of the first cells is inhibited by at least 1000.times. compared to the growth inhibition of the second cells 24 hours after exposing the first and second cells to the guided nuclease in an in vitro assay. 3. The method of claim 1, wherein and the immune cells comprise cells selected from CD8.sup.+ cells, tumor infiltrating lymphocytes (TILs), CD4.sup.+ cells, T.sub.reg cells and memory cells. 4. The method of claim 3, wherein the immune cells comprise CD8.sup.+ cells. 5. The method of claim 4, wherein the CD8.sup.+ cells are CD8.sup.+ cells of the patient. 6. The method of claim 1, wherein the immunotherapy comprises administration of an immune checkpoint modulator. 7. The method of claim 6, wherein the immune checkpoint modulator is a PD-1 (programmed death-1) inhibitor, PD-L1 (programmed death-ligand 1) inhibitor or CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) inhibitor. 8. The method of claim 6, wherein the immune checkpoint modulator is selected from the group consisting of ipilimumab, tremelimumab, nivolumab, pembrolizumab, pidilizumab, BMS-936559, durvalumab and atezolizumab. 9. The method of claim 1, wherein the first species is a gram negative bacterial species. 10. The method of claim 5, wherein the immune cells are upregulated or expanded in the patient. 11. The method of claim 1, wherein the cancer is selected from the group consisting of lung cancer, melanoma, breast cancer, prostate cancer, colon cancer, renal cell carcinoma, ovarian cancer, neuroblastoma, rhabdomyosarcoma, leukaemia, lymphoma melanoma, non-small cell lung cancer (NSCLC), bladder carcinoma and pancreatic cancer. 12. The method of claim 1, wherein the immune cells comprise memory cells selected from the group consisting of central memory T-cells (TCM), effector memory T-cells (TEM), stem cell memory cells (TSCM), and memory effector T-cells (T.sub.eff). 13. The method of claim 1, wherein the immune cells comprise memory cells selected from the group consisting of CD45RO.sup.+ CD62L.sup.+ and CD25.sup.+ CD45RA.sup.- CD45RO.sup.+ CD127.sup.- cells. 14. The method of claim 1, wherein the microbiota is a gut microbiota of the patient. 15. The method of claim 14, wherein the second cells are of a human gut commensul strain and/or a human gut probiotic strain. 16. The method of claim 1, wherein the immune cells comprise administered cells via adoptive cell therapy. 17. The method of claim 1, wherein the guided nuclease is a Cas, TALEN, meganuclease or zinc finger nuclease. 18. The method of claim 1, wherein the immunotherapy is selected from the group consisting of an immune checkpoint therapy, a vaccine therapy, an adoptive cell therapy, a CAR-T (chimeric antigen receptor T) cell therapy, and a TIL (Tumor-infiltrating lymphocyte) therapy. 19. The method of claim 1, wherein the efficacy of the immunotherapy is enhanced by reducing or preventing the risk of an unwanted side effect of the immunotherapy, or reducing autotoxicity in the patient mediated by T.sub.H2 cell cytokine release. 20. The method of claim 1, wherein the second cells have a 16s ribosomal RNA-encoding DNA sequence that is at least 80% identical to a 16s ribosomal RNA-encoding DNA sequence of the first cells.

Details for Patent 10,363,308

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Bristol-myers Squibb Company	YERVOY	ipilimumab	Injection	125377	03/25/2011		2036-06-05
Merck Sharp & Dohme Corp.	KEYTRUDA	pembrolizumab	For Injection	125514	09/04/2014		2036-06-05
Merck Sharp & Dohme Corp.	KEYTRUDA	pembrolizumab	Injection	125514	01/15/2015		2036-06-05
Bristol-myers Squibb Company	OPDIVO	nivolumab	Injection	125554	12/22/2014		2036-06-05
Bristol-myers Squibb Company	OPDIVO	nivolumab	Injection	125554	10/04/2017		2036-06-05
Bristol-myers Squibb Company	OPDIVO	nivolumab	Injection	125554	08/27/2021		2036-06-05
Genentech, Inc.	TECENTRIQ	atezolizumab	Injection	761034	05/18/2016		2036-06-05